Overview

A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

Status:
Terminated
Trial end date:
2018-07-02
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company